Monopar Therapeutics Inc(MNPR)
$71.78+-1.97 (+0.50%)
MNPR
Monopar Therapeutics Inc financials statements
$71.78
At close:+-1.97 (+0.50%)
Want to see MNPR full AI Analyst Report?
Monopar Therapeutics Inc (MNPR) Ratios
582 Followers
Monopar Therapeutics Inc Ratios
MNPR's free cash flow for Q2 2026 was $-3.25B. For the 2026 fiscal year, MNPR's free cash flow was increased by $0.00 and operating cash flow was $-3.25B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 |
| Quick Ratio | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 |
| Cash Ratio | 22.61 | 8.72 | 4.13 | 2.62 | 12.85 |
| Solvency Ratio | -4.75 | -2.97 | -4.78 | -3.35 | -5.76 |
| Operating Cash Flow Ratio | -4.46 | -1.22 | -4.47 | -2.31 | -4.63 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 137.57M | $ 55.04M | $ 5.58M | $ 10.03M | $ 18.94M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.02 | 1.10 | 1.31 | 1.31 | 1.08 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 4.50 | 2.94 | 0.82 | 0.78 | 2.22 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 82.12% | 96.44% | 95.14% | 99.80% | 99.74% |
| Return on Assets (ROA) | -9.75% | -25.85% | -114.39% | -79.50% | -44.36% |
| Return on Equity (ROE) | -9.95% | -28.32% | -150.37% | -104.22% | -48.06% |
| Return on Capital Employed (ROCE) | -12.11% | -29.37% | -158.05% | -104.35% | -48.19% |
| Return on Invested Capital (ROIC) | -12.11% | -29.37% | -158.05% | -104.35% | -48.19% |
| Return on Tangible Assets | -9.75% | -25.85% | -114.39% | -79.50% | -44.36% |
| Earnings Yield | -2.83% | -6.19% | -34.06% | -6.98% | -4.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.65 | -0.56 | -0.54 | -0.57 | -0.59 |
| Free Cash Flow Per Share | -1.65 | -0.56 | -0.54 | -0.57 | -0.59 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -78.76 | 0.00 | 0.00 | -859.72 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -2.52% | -2.54% | -31.86% | -4.80% | -3.66% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -35.30 | -16.18 | -2.94 | -14.33 | -21.99 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.51 | 4.57 | 4.41 | 14.94 | 10.57 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -39.66 | -39.31 | -3.14 | -20.85 | -27.36 |
| Price-to-Operating Cash Flow Ratio | -39.66 | -39.31 | -3.14 | -20.85 | -27.36 |
| Price-to-Earnings Growth (PEG) Ratio | -0.98 | -0.12 | 0.10 | -1.05 | -0.85 |
| Enterprise Value Multiple | -30.78 | -13.21 | -1.97 | -13.53 | -19.71 |
| Enterprise Value | 422.26M | 205.94M | 17.40M | 142.53M | 179.87M |
| EV to EBITDA | -30.78 | -13.21 | -1.97 | -13.53 | -19.71 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -34.61 | -32.16 | -2.21 | -19.72 | -24.58 |
| EV to Operating Cash Flow | -34.61 | -32.16 | -2.21 | -19.72 | -24.58 |
| Tangible Book Value Per Share | 18.60 | 4.81 | 0.39 | 0.79 | 1.52 |
| Shareholders’ Equity Per Share | 18.60 | 4.81 | 0.39 | 0.79 | 1.52 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.85 | -1.36 | -0.58 | -0.83 | -0.73 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.95 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.89 | 0.41 | 0.94 | 0.69 | 0.80 |
Currency in USD
